泛癌中SLC7A7表达的预后意义及其与免疫微环境的关系

Prognostic Significance of SLC7A7 Expression in Pan-cancer and its Relationship with Immune Microenvironment

SLC7A7是溶质转运蛋白超家族的重要成员之一,能够通过某些信号通路调控细胞周期、抑制肿瘤细胞迁移和侵袭,可能对肿瘤的预后具有重要意义。然而,SLC7A7在肿瘤进展和肿瘤免疫学中的潜在功能和机制仍不清楚。应用TIMER比较了多种癌症类型和正常组织中SLC7A7基因表达量的差异。使用cBioPortal分析SLC7A7拷贝数变化和突变的频率。使用MANTIS评估TCGA队列中的微卫星不稳定性。CIBERSORT算法用于估计浸润免疫细胞类型和免疫评分的相对分数。进行Kaplan-Meier生存曲线分析以评估泛癌的预后价值,SLC7A7在多种癌症中异常表达。在子宫内膜癌中SLC7A7突变频率最高。通过分析肿瘤微环境中SLC7A7表达与免疫细胞浸润之间的关系,发现对于不同的癌症,SLC7A7表达与浸润肿瘤的免疫细胞之间的相关性有所不同。发现24种癌症类型中SLC7A7的高表达与M1型巨噬细胞浸润相关。最后,泛癌生存分析表明,SLC7A7高表达在肾上腺皮质癌(ACC),肾嫌色细胞癌(KICH),胶质瘤(LGG),肝癌(LIHC),胰腺癌(PAAD),胸腺癌(THYM)和葡萄膜黑色素瘤(UVM)预后较差。SLC7A7低表达在肉瘤(SARC),皮肤黑色素瘤(SKCM)中预后较差。这些发现表明,SLC7A7在肿瘤免疫微环境中起着重要作用,并且已确定SLC7A7在某些类型的癌症中具有预后价值。因此,SLC7A7是癌症免疫疗法和有效的预后生物标志物的潜在目标。

SLC7A7 is one of the important members of the solute transporter superfamily. It can regulate the cell cycle and inhibit tumor cell migration and invasion through certain signaling pathways, which may be of great significance to the prognosis of tumors. However, the potential functions and mechanisms of SLC7A7 in tumor progression and tumor immunology are still unclear.TIMER was used to compare the difference of SLC7A7 gene expression in a variety of cancer types and normal tissues. CBioPortal was used to analyze the frequency of SLC7A7 copy number changes and mutations. MANTIS was used to evaluate microsatellite instability in the TCGA cohort. MANTIS was used to evaluate microsatellite instability in the TCGA cohort. The CIBERSORT algorithm was used to estimate the relative scores of infiltrating immune cell types and immune scores. Kaplan--Meier survival curve analysis was performed to evaluate the prognostic value of pan-cancer. SLC7A7 was abnormally expressed in a variety of cancers.SLC7A7 mutation frequency was highest in endometrial cancer. By analyzing the relationship between SLC7A7 expression and immune cell infiltration in the tumor microenvironment, it was found that for different cancers, the correlation between SLC7A7 expression and immune cells infiltrating the tumor was different. It was found that the high expression of SLC7A7 in 24 cancer types was associated with M1 macrophage infiltration. Finally, pan-cancer survival analysis showed that highly expressed SLC7A7 had poor prognosis in adrenocortical carcinoma(ACC), renal chromophobe cell carcinoma(KICH), glioma(LGG), liver cancer(LIHC),pancreatic cancer(PAAD), thymic cancer(THYM) and uveal melanoma(UVM). The low expression of SLC7A7 was poor in sarcoma(SARC) and skin melanoma(SKCM). These findings indicated that SLC7A7 played an important role in the tumor immune microenvironment, and it has been determined that SLC7A7 had prognostic value in certain types of cancer. Therefore, SLC7A7 is a potential target for cancer immunotherapy and an effective prognostic biomarker.